News & Events about Pulmonx Corp.
Versor Investments LP purchased a new stake in Pulmonx Co. (NASDAQ:LUNG Get Rating) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 15,500 shares of the companys stock, valued at approximately $131,000. Several other institutional investors and hedge funds ...
Ticker Report
4 months ago
Pulmonx Co. (NASDAQ:LUNG Get Rating) has earned a consensus rating of Hold from the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ...
Ticker Report
4 months ago
Pulmonx (NASDAQ:LUNG Get Rating) had its price objective lowered by Morgan Stanley from $14.00 to $9.50 in a report issued on Friday, Benzinga reports. The firm currently has an equal weight rating on the stock. Morgan Stanleys price target points to a potential upside ...
Globe Newswire
7 months ago
REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is ...
Business Wire
9 months ago
Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the...